VYNE THERAPEUTICS INC (VYNE) Stock Income Statement
NASDAQ:VYNE - Nasdaq - US92941V3087 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 501.00K | 424.00K | 480.00K | 930.00K | 20.99M | |||
| Cost Of Goods | N/A | N/A | N/A | 3.35M | 1.39M | |||
| Gross Profit | N/A | N/A | N/A | 11.41M | 19.60M | |||
| Operating Expenses | 44.14M | 29.68M | 34.77M | 39.84M | 272.15M | |||
| Research and Development | 30.95M | 16.31M | 18.39M | 19.54M | 43.53M | |||
| Selling, General, and Administrative Expenses | 13.19M | 13.38M | 16.39M | 20.30M | 89.54M | |||
| Operating Income | -43.64M | -29.26M | -34.30M | -38.91M | -252.55M | |||
| Interest Income/Expense | N/A | N/A | 0.00 | -5.61M | -4.39M | |||
| Other Income/Expense | 3.83M | 1.39M | 360.00K | -140.00K | 1.11M | |||
| Income Before Taxes | -39.80M | -27.87M | -33.93M | -44.66M | -255.83M | |||
| Income Tax | 4.00K | 0.00 | 10.00K | -450.00K | -260.00K | |||
| Net Income | -39.83M | -28.45M | -23.21M | -73.33M | -255.57M | |||
| EBITDA | -43.63M | N/A | -34.23M | -38.80M | -252.21M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.93 | -2.76 | -7.27 | -25.63 | -141.98 | |||
| Non GAAP EPS | -0.94 | -7.04 | -11.07 | -16.75 | -5.75 | |||
| Statistics | ||||||||
| Gross Profit Margin | N/A | N/A | N/A | 1226.56% | 93.38% | |||
| Profit Margin | -7950.90% | -6710.38% | -4835.42% | -7884.95% | -1217.58% | |||
| Operating Profit Margin | -8709.98% | -6900.47% | -7145.83% | -4183.87% | -1203.19% | |||
All data in USD